%PDF-1.4
%
135 0 obj
<>
endobj
134 0 obj
<>stream
2018-01-20T10:16:05+05:30
Arbortext Advanced Print Publisher 10.0.1465/W Unicode
2018-03-09T15:46:07-08:00
2018-03-09T15:46:07-08:00
Acrobat Distiller 8.1.0 (Windows)
application/pdf
B-Cell Therapies in Multiple Sclerosis
uuid:82ad9714-0e12-4fa2-8fa8-dedda7416106
uuid:373f2470-1dd2-11b2-0a00-c900c879d9ff
endstream
endobj
130 0 obj
<>
endobj
132 0 obj
<>
endobj
2 0 obj
<>
endobj
86 0 obj
<>
endobj
85 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>>>/Rotate 0/Type/Page>>
endobj
93 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>>>/Rotate 0/Type/Page>>
endobj
101 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>>>/Rotate 0/Type/Page>>
endobj
108 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>>>/Rotate 0/Type/Page>>
endobj
183 0 obj
<>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/Type/Page>>
endobj
201 0 obj
[207 0 R 208 0 R 209 0 R]
endobj
202 0 obj
<>stream
q
300 0 0 75 156 667 cm
/Im0 Do
Q
BT
/T1_0 1 Tf
11 0 0 11 208.33379 589.99988 Tm
( published online January 22, 2018)Tj
/T1_1 1 Tf
-14.39398 0 Td
(Cold Spring Harb Perspect Med\240)Tj
/T1_2 1 Tf
0 1 TD
(\240)Tj
/T1_0 1 Tf
0 1.00001 TD
(Joseph J. Sabatino, Jr., Scott S. Zamvil and Stephen L. Hauser)Tj
/T1_2 1 Tf
0 1 TD
(\240)Tj
15 0 0 15 50 634 Tm
(B-Cell Therapies in Multiple Sclerosis)Tj
ET
50 578 m
562 578 l
0 0 m
S
BT
ET
BT
/T1_2 1 Tf
10 0 0 10 50 564 Tm
(Subject Collection)Tj
ET
BT
/T1_0 1 Tf
10 0 0 10 227.78989 564 Tm
( )Tj
0 0 1 rg
-7.77899 0 Td
(Multiple Sclerosis)Tj
ET
50 555 m
562 555 l
0 0 m
S
BT
ET
BT
0 g
/T1_2 1 Tf
10 0 0 10 50 539 Tm
(Alemtuzumab as Treatment for Multiple Sclerosis)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 60 529 Tm
(Serafeim Katsavos and Alasdair Coles)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 308 539 Tm
(Oral Therapies for Multiple Sclerosis)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 318 529 Tm
(Simon Faissner and Ralf Gold)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 50 504.99997 Tm
(Bedside)Tj
T*
(Natalizumab: Perspectives from the Bench to)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 60 495 Tm
(Afsaneh Shirani and Olaf St\374ve)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 308 515 Tm
(Biomarkers in Multiple Sclerosis)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 318 505 Tm
(Anu Paul, Manuel Comabella and Roopali Gandhi)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 50 481 Tm
(Multiple Sclerosis Pathology)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 60 471 Tm
(Hans Lassmann)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 308 470.99997 Tm
(Acetate)Tj
T*
(The Evolving Mechanisms of Action of Glatiramer)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 318 461 Tm
(Thomas Prod'homme and Scott S. Zamvil)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 50 436.99997 Tm
(Sclerosis)Tj
T*
(Neurodegeneration in Progressive Multiple)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 60 427 Tm
(Graham Campbell and Don Mahad)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 308 436.99997 Tm
(New Directions)Tj
T*
(Genetics of Multiple Sclerosis: An Overview and)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 318 427 Tm
(Nikolaos A. Patsopoulos)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 50 402.99997 Tm
(Sclerosis)Tj
T*
(Microglial Phenotypes and Functions in Multiple)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 60 382.99997 Tm
(Lassmann, et al.)Tj
T*
(Elaine O'Loughlin, Charlotte Madore, Hans)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 308 413 Tm
(B-Cell Therapies in Multiple Sclerosis)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 318 392.99997 Tm
(Stephen L. Hauser)Tj
T*
(Joseph J. Sabatino, Jr., Scott S. Zamvil and)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 50 369 Tm
(Effector T Cells in Multiple Sclerosis)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 60 359 Tm
(Belinda J. Kaskow and Clare Baecher-Allan)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 308 358.99997 Tm
(Sclerosis)Tj
T*
(Regulation of Astrocyte Functions in Multiple)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 318 349 Tm
(Michael A. Wheeler and Francisco J. Quintana)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 50 324.99997 Tm
(Sclerosis)Tj
T*
(Magnetic Resonance Imaging in Multiple)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 60 315 Tm
(Christopher C. Hemond and Rohit Bakshi)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 308 335 Tm
(Clinical Course of Multiple Sclerosis)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 318 325 Tm
(Sylvia Klineova and Fred D. Lublin)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 104.93973 301 Tm
( for Multiple Sclerosis)Tj
/T1_3 1 Tf
-0.549 0 Td
(b)Tj
/T1_2 1 Tf
-4.94497 0 Td
(Interferon )Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 60 280.99997 Tm
(Ramanathan, et al.)Tj
T*
(Dejan Jakimovski, Channa Kolb, Murali)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 308 290.99997 Tm
(Autoimmunity)Tj
T*
(Regulatory T Cells: From Discovery to)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 318 281 Tm
(Alexandra Kitz, Emily Singer and David Hafler)Tj
ET
BT
0 0 1 rg
/T1_0 1 Tf
10 0 0 10 242.84967 112 Tm
(http://perspectivesinmedicine.cshlp.org/cgi/collection/ )Tj
0 g
-19.28497 0 Td
(For additional articles in this collection, see )Tj
ET
50 96 m
562 96 l
0 0 m
S
BT
ET
BT
/T1_0 1 Tf
10 0 0 10 52 74 Tm
(Copyright \251 2018 Cold Spring Harbor Laboratory Press; all rights rese\
rved)Tj
ET
BT
/T1_0 1 Tf
8 0 0 8 261.09613 755.99997 Tm
(Harbor Laboratory Press )Tj
3.25098 1 Td
( at UNIV OF CALIF-SF on March 9, 2018 - Published by Cold Spring)Tj
0 0 1 rg
-17.50698 0 Td
(http://perspectivesinmedicine.cshlp.org/)Tj
0 g
-8.11398 0 Td
(Downloaded from )Tj
ET
endstream
endobj
206 0 obj
<>/Filter/FlateDecode/Height 300/Length 31110/Name/X/Subtype/Image/Type/XObject/Width 1200>>stream
Hn[a@x
Ct8$@d8C8HJ4H`=P=f(
P7\etA}}{ %= Oz @>A |҃ I '= Oz @>A |҃ I '= Oz @>A |҃ I '= Oz @>A |҃ I '= Oz @>A |҃ I '= Oz @>OM;tIw\Z
|cz܋я*ok 8-zSN;zjjP?
zwvDڜTV @8t$;vl,ΔJW,x=jkOoI;D~#*gU \z0FE;kRIuv͔QNJ$ifes/ޤyk3^O|
҃6w[dZڷ(O;+)GC/1$ omm .=xȱ{SQYKG0=؍0Ryq Jp@ @c}unPy)1F͔Jc?m4"K'
%{>撒 rEv;is~5ȱBxd7{igTi =bѸ1ry4{Nn{Ո,;!p37bp{glzmz $k{zB6V럍ݩ0J0z0R\,x(zgyeg/g pAInݸNňhR)xMtc~8tk&'*io \,zpHŌ1xtȱU3omfn{o}cJS,#33k6,N[[ +bp=y=zGĥoQpQav;13}[|?~h`.֗C GZdvWt:Yv
j,FQ~ul]D`~CC{ 15q,5S=Gܮ/Wnp{g93ҳϳ\̏-.֗&) p !__~bͩLJӉSR*:Y[oŞ^wo=t?' ro}cZ|m4Z!1!挮-i`{.!cl<鸻kZiQѰC1?<7m'I?mūWŸT pkGW*GOg`{{lcpAFU(-,냕a9t~
̔JX[Kv\xbO Α<**jhًr wW__]7nחŘpHٓpRN+[ l'IMP*GW"{e~ۍYQ}0Ri{lF.֗&iI8vH$l6O|+KB ]>zKdl]9
R=5'k^O?(=c0㐹J¤
}-?Kv5z0}$! |.eF
5(ǣ1~56dboIa_˳'5wWwy Qb1d8_`\o4S=I;jXe qzLSh*:=֍^][T
$_G